A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.